ACC 2024 Insights: Evolving Pharmacology for HFrEF vs. HFpFF - With or Without Chronic Kidney Disease and/or Diabetes

2,115 views
April 16, 2024

Chapters

Introduction & Guideline-Directed Medical Therapy

00:00

ARNI in HFrEF & HFpEF

01:33

ARNI's Renal Effects & Albuminuria

07:17

ARNI & Diabetes Management

12:43

SGLT2 Inhibitors' Broad Impact

15:09

Mechanisms of SGLT2 Inhibitors

20:48

Finerenone & Cardio-Kidney-Metabolic Syndrome

24:54

Conclusion: Therapies Across Conditions

29:23

Comments 2
Login to view comments. Click here to Login